Relapsed Diffuse Large B-cell Lymphoma: Clinical Trials

4 trials for Relapsed Diffuse Large B-cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 4
Phase 13Completed 3

Follow Relapsed Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Relapsed Diffuse Large B-cell Lymphoma trials Research Report on Relapsed Diffuse Large B-cell Lymphoma

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
Ociperlimab, Tislelizumab, Rituximab - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2CompletedBeiGene532022-04-252025-09-15
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
Zanubrutinib - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Phase 2CompletedBeiGene652021-08-112026-03-25
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide - Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2CompletedKite, A Gilead Company3072015-04-212024-06-04
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ibrutinib, Lenalidomide, Rituximab - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2CompletedPharmacyclics LLC.1382014-03-132022-02-04

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (4)  ·  Lymphoma (1)  ·  Neoplasms (1)

Broader conditions

Hemic and Lymphatic Diseases (4)  ·  Immune System Diseases (4)  ·  Immunoproliferative Disorders (4)  ·  Lymphatic Diseases (4)  ·  Lymphoma, B-Cell (4)  ·  Lymphoma, Non-Hodgkin (4)  ·  Lymphoproliferative Disorders (4)  ·  Neoplasms by Histologic Type (4)  ·  Lymphoma (3)  ·  Neoplasms (3)

Interventions

Rituximab (3)  ·  Bendamustine Hydrochloride (1)  ·  Carboplatin (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Dexamethasone (1)  ·  Doxorubicin (1)  ·  Etoposide (1)  ·  Gemcitabine (1)  ·  Ifosfamide (1)  ·  Lenalidomide (1)  ·  Levetiracetam (1)  ·  Methylprednisolone (1)  ·  Oxaliplatin (1)  ·  Prednisone (1)

Sponsors

BeiGene (2)  ·  Kite, A Gilead Company (1)  ·  Pharmacyclics LLC. (1)

Countries

China (2)  ·  Germany (2)  ·  United States (2)  ·  Belgium (1)  ·  Canada (1)  ·  France (1)  ·  Israel (1)  ·  Netherlands (1)  ·  United Kingdom (1)

Top investigators

Jutta K. Neuenburg, MD, PhD (1)

Results publications

PMID 29226797, PMID 30518502, PMID 31331917, PMID 33035333, PMID 33334730, PMID 34296427, PMID 34310745, PMID 34493319, PMID 34515338, PMID 36618900, PMID 36821768, PMID 38635762, PMID 39240498

NIH funding

2015 (1)